A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets

Epidermal Nevus Syndrome (ENS), also known as Cutaneous Skeletal Hypophosphatemia Syndrome or Linear Sebaceous Nevus Syndrome, is caused by a mosaic somatic mutation of RAS (Rat Sarcoma genes) which leads to abnormally elevated levels of fibroblast growth factor 23 (FGF23). FGF23 is a major regulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Carson, Gillis, Andrea, Fazendin, Jessica, Abdullatif, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309659/
https://www.ncbi.nlm.nih.gov/pubmed/35899095
http://dx.doi.org/10.1016/j.bonr.2022.101605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309659/
https://www.ncbi.nlm.nih.gov/pubmed/35899095
http://dx.doi.org/10.1016/j.bonr.2022.101605

Ejemplares similares